JP2017523180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523180A5 JP2017523180A5 JP2017504354A JP2017504354A JP2017523180A5 JP 2017523180 A5 JP2017523180 A5 JP 2017523180A5 JP 2017504354 A JP2017504354 A JP 2017504354A JP 2017504354 A JP2017504354 A JP 2017504354A JP 2017523180 A5 JP2017523180 A5 JP 2017523180A5
- Authority
- JP
- Japan
- Prior art keywords
- aluminum
- vaccine
- flagellin
- pharmaceutical composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010040721 Flagellin Proteins 0.000 claims 13
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 13
- 229910052782 aluminium Inorganic materials 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229960005486 vaccine Drugs 0.000 claims 12
- 239000002671 adjuvant Substances 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 230000028993 immune response Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 241000701806 Human papillomavirus Species 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 229940032046 DTaP vaccine Drugs 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 241000193738 Bacillus anthracis Species 0.000 claims 2
- 201000006082 Chickenpox Diseases 0.000 claims 2
- 229940124846 Diphtheria-Tetanus-Pertussis vaccine Drugs 0.000 claims 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 2
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 2
- 206010046980 Varicella Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920001661 Chitosan Polymers 0.000 claims 1
- 108010060123 Conjugate Vaccines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 206010011985 Decubitus ulcer Diseases 0.000 claims 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000005807 Japanese encephalitis Diseases 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000000474 Poliomyelitis Diseases 0.000 claims 1
- 208000004210 Pressure Ulcer Diseases 0.000 claims 1
- 206010037742 Rabies Diseases 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 229940032047 Tdap vaccine Drugs 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 208000037386 Typhoid Diseases 0.000 claims 1
- 208000003152 Yellow Fever Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940031670 conjugate vaccine Drugs 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 claims 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 claims 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229960003127 rabies vaccine Drugs 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 201000008297 typhoid fever Diseases 0.000 claims 1
- 229960001515 yellow fever vaccine Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031116P | 2014-07-30 | 2014-07-30 | |
| US62/031,116 | 2014-07-30 | ||
| US201562110744P | 2015-02-02 | 2015-02-02 | |
| US62/110,744 | 2015-02-02 | ||
| US201562117366P | 2015-02-17 | 2015-02-17 | |
| US62/117,366 | 2015-02-17 | ||
| PCT/US2015/042887 WO2016019134A1 (en) | 2014-07-30 | 2015-07-30 | Flagellin-based agents and uses including effective vaccination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523180A JP2017523180A (ja) | 2017-08-17 |
| JP2017523180A5 true JP2017523180A5 (enExample) | 2018-09-06 |
| JP6646039B2 JP6646039B2 (ja) | 2020-02-14 |
Family
ID=55218277
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504404A Expired - Fee Related JP6940916B2 (ja) | 2014-07-30 | 2015-07-29 | フラジェリン組成物および使用 |
| JP2017504354A Expired - Fee Related JP6646039B2 (ja) | 2014-07-30 | 2015-07-30 | フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用 |
| JP2021142801A Pending JP2021191781A (ja) | 2014-07-30 | 2021-09-01 | フラジェリン組成物および使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504404A Expired - Fee Related JP6940916B2 (ja) | 2014-07-30 | 2015-07-29 | フラジェリン組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021142801A Pending JP2021191781A (ja) | 2014-07-30 | 2021-09-01 | フラジェリン組成物および使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US10202426B2 (enExample) |
| EP (2) | EP3174893B1 (enExample) |
| JP (3) | JP6940916B2 (enExample) |
| KR (1) | KR20170031251A (enExample) |
| CN (2) | CN107087411B (enExample) |
| AU (2) | AU2015296555B2 (enExample) |
| BR (1) | BR112017001796A2 (enExample) |
| CA (2) | CA2994218A1 (enExample) |
| EA (2) | EA035372B1 (enExample) |
| ES (1) | ES2816630T3 (enExample) |
| IL (2) | IL250334B (enExample) |
| MX (2) | MX385845B (enExample) |
| WO (2) | WO2016019034A1 (enExample) |
| ZA (1) | ZA201701286B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170031251A (ko) * | 2014-07-30 | 2017-03-20 | 클리브랜드 바이오랩스, 아이엔씨. | 플라젤린 조성물 및 용도 |
| US11058758B2 (en) | 2014-11-20 | 2021-07-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | TH1-inducing adjuvant comprising combination of different nucleic acid adjuvants, and use of same |
| UY37816A (es) | 2017-07-20 | 2019-02-28 | Spogen Biotech Inc | Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| WO2019094528A1 (en) * | 2017-11-09 | 2019-05-16 | The Scripps Research Institute | An improved heroin vaccine |
| JP7037930B2 (ja) * | 2017-12-19 | 2022-03-17 | 株式会社小糸製作所 | 車両の運転支援装置、命令表示装置及び車両用灯具。 |
| CN109879940A (zh) * | 2017-12-25 | 2019-06-14 | 苏州和锐生物科技有限公司 | 鞭毛g多肽、抗体捕获器件及试剂盒 |
| EA202092530A1 (ru) * | 2018-04-24 | 2021-02-01 | Джиноум Протекшн, Инк. | Способы облегчения старческой астении и старения |
| WO2020110154A1 (en) * | 2018-11-30 | 2020-06-04 | Bharat Biotech International Limited | A chimeric therapeutic vaccine |
| WO2020118192A1 (en) * | 2018-12-07 | 2020-06-11 | Genome Protection, Inc. | Engineered flagellin-derived compositions and uses |
| CN111718417B (zh) * | 2019-03-19 | 2022-10-14 | 宁波鲲鹏生物科技有限公司 | 含有荧光蛋白片段的融合蛋白及其用途 |
| KR102169663B1 (ko) * | 2019-03-28 | 2020-10-26 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물 |
| KR20220009955A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료 |
| CN110157655B (zh) * | 2019-05-22 | 2021-06-01 | 中国兽医药品监察所 | 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用 |
| CN114502573A (zh) * | 2019-08-30 | 2022-05-13 | 基因组保护股份有限公司 | 提高疫苗功效的方法 |
| CN118754841A (zh) | 2020-05-19 | 2024-10-11 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| KR102720967B1 (ko) * | 2020-06-04 | 2024-10-23 | 가톨릭대학교 산학협력단 | 플라젤린으로부터 유도된 tlr5 작용제를 유효성분으로 포함하는 면역관문억제제의 항암 효과 증진용 약학 조성물 |
| TWI746188B (zh) * | 2020-09-28 | 2021-11-11 | 中山醫學大學 | 篩選治療腦炎藥物之平台及其方法 |
| EP4277654A1 (en) | 2021-01-18 | 2023-11-22 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
| US20240277801A1 (en) * | 2021-06-30 | 2024-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Aerosol composition for pulmonary delivery of flagellin |
| KR102483177B1 (ko) * | 2021-07-09 | 2022-12-29 | 전남대학교산학협력단 | 탈-면역 플라젤린 및 이를 포함하는 백신 조성물 |
| KR102514849B1 (ko) * | 2021-10-28 | 2023-03-28 | 전남대학교산학협력단 | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 |
| IL317229A (en) * | 2022-06-01 | 2025-01-01 | Flag Bio Inc | RNA helpers, methods and uses thereof |
| KR20240022417A (ko) * | 2022-08-10 | 2024-02-20 | 주식회사 메디스팬 | 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도 |
| WO2025172452A1 (en) * | 2024-02-14 | 2025-08-21 | Institut National de la Santé et de la Recherche Médicale | Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3007812A (en) | 1957-02-11 | 1961-11-07 | Allied Chem | Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| ES2070312T5 (es) * | 1988-12-19 | 2003-05-16 | American Cyanamid Co | Vacuna de proteina de membrana exterior meningococica de clase 1. |
| ES2088014T3 (es) | 1990-09-28 | 1996-08-01 | Sulzer Innotec Ag | Aguja hueca para utilizacion medica y procedimiento para la fabricacion de este tipo de agujas huecas. |
| CA2383007A1 (en) | 1992-03-02 | 1993-09-16 | Chiron S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| US5693476A (en) | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
| US20020009747A1 (en) | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
| US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| AU4709401A (en) | 1999-11-29 | 2001-06-12 | Inotek Corporation | Composition and method for treating a microbial infection |
| CA2398660A1 (en) | 2000-01-31 | 2001-08-02 | Munin Corporation | Human cyr61 |
| US7300749B2 (en) | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
| AU2002216500A1 (en) | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
| US8703146B2 (en) | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| WO2002085933A1 (en) | 2001-04-20 | 2002-10-31 | The Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| WO2003028659A2 (en) | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
| US7078165B2 (en) | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
| WO2005056041A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ |
| WO2005056054A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB |
| EP1706133B1 (en) | 2003-12-02 | 2010-10-06 | Cleveland Clinic Foundation | Methods of protecting against radiation using flagellin |
| US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
| US20050266391A1 (en) | 2004-01-15 | 2005-12-01 | Bennett Brydon L | Methods for preserving tissue |
| US7404963B2 (en) | 2004-10-01 | 2008-07-29 | The University Of South Florida | Flagellin-based adjuvants and vaccines |
| EP1824510B1 (en) | 2004-12-16 | 2012-10-31 | Wake Forest University Health Sciences | Use of flagellin in the immunotherapy of yersinia pestis |
| EP2460534A1 (en) | 2004-12-22 | 2012-06-06 | Cleveland Clinic Foundation | Flagellin related polypeptides and uses thereof |
| WO2007030581A2 (en) | 2005-09-09 | 2007-03-15 | Oregon Health & Science University | Neuroprotectants |
| WO2007070623A2 (en) | 2005-12-14 | 2007-06-21 | Medistem Laboratories, Inc. | Transcatheter tumor immunoembolization |
| EP2441846A3 (en) | 2006-01-09 | 2012-07-25 | The Regents Of the University of California | Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy |
| WO2008094275A1 (en) | 2007-01-30 | 2008-08-07 | New York University | Peptides for treatment of conditions associated with nitric oxide |
| KR20100034010A (ko) | 2007-06-15 | 2010-03-31 | 임뮤룩스, 인코포레이티드 | Ｔｎｆｒ 효능제 치료 요법의 독성을 경감시키기 위한 ｔｌｒ 효능제 및／또는 타입 1 인터페론의 용도 |
| MX2010001194A (es) | 2007-07-31 | 2010-07-30 | Univ Louisiana State | Conjugado de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciones. |
| EA201692127A1 (ru) | 2007-11-07 | 2017-08-31 | Селлдекс Терапьютикс Инк. | Антитела, связывающиеся с человеческим dec-205 |
| WO2009102818A1 (en) | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
| EP2320948B1 (en) * | 2008-08-01 | 2013-03-06 | Cleveland Biolabs, Inc. | Methods for treating reperfusion injuries |
| US8486408B2 (en) * | 2008-10-03 | 2013-07-16 | Emory University | Methods for the treatment of graft-versus-host disease |
| BRPI1010937A2 (pt) | 2009-05-21 | 2019-09-24 | Astrazeneca Ab | composto, uso de um composto, e, método para tratar câncer |
| NZ598654A (en) | 2009-09-02 | 2014-05-30 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
| KR20120104177A (ko) | 2009-10-06 | 2012-09-20 | 파나셀라 랩스, 아이엔씨. | 암을 치료하기 위한 톨 유사 수용체 및 효능제의 용도 |
| CN102892429B (zh) * | 2010-03-17 | 2016-08-31 | 康奈尔大学 | 基于被破坏的腺病毒的抗滥用药物疫苗 |
| CN103945863A (zh) * | 2011-08-01 | 2014-07-23 | 爱默蕾大学 | 包含配体的vlp及其相关方法 |
| CN102965386A (zh) * | 2011-09-02 | 2013-03-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法 |
| CN102772795B (zh) * | 2012-08-06 | 2015-07-29 | 中国人民解放军疾病预防控制所 | 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用 |
| KR20170031251A (ko) * | 2014-07-30 | 2017-03-20 | 클리브랜드 바이오랩스, 아이엔씨. | 플라젤린 조성물 및 용도 |
-
2015
- 2015-07-29 KR KR1020177005615A patent/KR20170031251A/ko not_active Ceased
- 2015-07-29 JP JP2017504404A patent/JP6940916B2/ja not_active Expired - Fee Related
- 2015-07-29 ES ES15827248T patent/ES2816630T3/es active Active
- 2015-07-29 CN CN201580048628.1A patent/CN107087411B/zh not_active Expired - Fee Related
- 2015-07-29 EA EA201790273A patent/EA035372B1/ru unknown
- 2015-07-29 US US15/329,870 patent/US10202426B2/en active Active
- 2015-07-29 MX MX2017001279A patent/MX385845B/es unknown
- 2015-07-29 EP EP15827248.4A patent/EP3174893B1/en active Active
- 2015-07-29 WO PCT/US2015/042684 patent/WO2016019034A1/en not_active Ceased
- 2015-07-29 CA CA2994218A patent/CA2994218A1/en active Pending
- 2015-07-29 AU AU2015296555A patent/AU2015296555B2/en not_active Ceased
- 2015-07-29 BR BR112017001796-2A patent/BR112017001796A2/pt not_active Application Discontinuation
- 2015-07-30 AU AU2015296298A patent/AU2015296298B2/en not_active Ceased
- 2015-07-30 JP JP2017504354A patent/JP6646039B2/ja not_active Expired - Fee Related
- 2015-07-30 MX MX2017001406A patent/MX2017001406A/es unknown
- 2015-07-30 US US15/500,133 patent/US10336793B2/en active Active
- 2015-07-30 WO PCT/US2015/042887 patent/WO2016019134A1/en not_active Ceased
- 2015-07-30 EP EP15827000.9A patent/EP3174552B1/en active Active
- 2015-07-30 CN CN201580052842.4A patent/CN107073092A/zh active Pending
- 2015-07-30 CA CA2994289A patent/CA2994289C/en active Active
- 2015-07-30 EA EA201790294A patent/EA037407B1/ru unknown
-
2017
- 2017-01-29 IL IL250334A patent/IL250334B/en unknown
- 2017-01-29 IL IL250331A patent/IL250331B/en active IP Right Grant
- 2017-02-21 ZA ZA2017/01286A patent/ZA201701286B/en unknown
-
2018
- 2018-06-25 US US16/017,251 patent/US20180354995A1/en not_active Abandoned
- 2018-12-20 US US16/226,909 patent/US10669316B2/en not_active Expired - Fee Related
-
2019
- 2019-05-16 US US16/414,403 patent/US10730915B2/en not_active Expired - Fee Related
-
2020
- 2020-02-27 US US16/802,859 patent/US11034733B2/en not_active Expired - Fee Related
- 2020-06-24 US US16/910,347 patent/US10975127B2/en not_active Expired - Fee Related
-
2021
- 2021-03-09 US US17/195,935 patent/US11542306B2/en active Active
- 2021-05-13 US US17/319,250 patent/US20210340190A1/en not_active Abandoned
- 2021-09-01 JP JP2021142801A patent/JP2021191781A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523180A5 (enExample) | ||
| Shah et al. | Overview of vaccine adjuvants: introduction, history, and current status | |
| CN106659777A8 (zh) | 免疫原性组合产品 | |
| JP2015214545A5 (enExample) | ||
| JP2011250797A5 (enExample) | ||
| JP2017524682A5 (enExample) | ||
| WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
| TW200722101A (en) | Novel composition | |
| IL164812A0 (en) | Packaged virus-like particles for use as adjuvants: method of preparation and use | |
| JP2013518052A5 (enExample) | ||
| NO323084B1 (no) | Vaksine-sammensetninger | |
| MX363667B (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| Kim et al. | Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity | |
| JP2015512441A5 (enExample) | ||
| JP2016106117A5 (enExample) | ||
| WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
| WO2014145951A3 (en) | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom | |
| JP2011525902A (ja) | 遅延型追加刺激免疫処置に対する迅速な応答 | |
| JP2010506926A5 (enExample) | ||
| JP2024150687A (ja) | アジュバントおよび該アジュバントを含むワクチン | |
| JP2012526149A5 (enExample) | ||
| RU2019113989A (ru) | Лекарственное средство | |
| WO2009074861A3 (en) | Improved vaccine | |
| Kieny et al. | Research and development of new vaccines against infectious diseases | |
| Omoniyi et al. | Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches |